FENNEC PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
FENNEC PHARMACEUTICALS INC. (FENC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2025-11-13
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-03-31 was 0.00%.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2020-09-30 was 0.00%.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2020-06-30 was 0.00%.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2020 was 0.00%.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2019 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|---|---|
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-13 | |||||
| 2024-09-30 | 0.00% 10-Q · filed 2024-11-08 | |||||
| 2023-09-30 | 0.00% 10-Q · filed 2023-11-09 | |||||
| 2023-06-30 | 0.00% 10-Q · filed 2023-08-07 | |||||
| 2023-03-31 | 0.00% 10-Q · filed 2023-05-12 | |||||
| 2022-12-31 | 0.00% 10-K · filed 2023-03-29 | |||||
| 2022-09-30 | 0.00% 10-Q · filed 2022-11-14 | |||||
| 2022-06-30 | 0.00% 10-Q · filed 2022-08-12 | |||||
| 2022-03-31 | 0.00% 10-Q · filed 2022-05-12 | |||||
| 2021-12-31 | 0.00% 10-K · filed 2023-03-29 | |||||
| 2021-09-30 | 0.00% 10-Q · filed 2021-11-10 | |||||
| 2021-06-30 | 0.00% 10-Q · filed 2021-08-10 | |||||
| 2020-12-31 | 0.00% 10-K · filed 2022-02-28 | |||||
| 2020-09-30 | 0.00% 10-Q · filed 2020-11-16 | |||||
| 2020-06-30 | 0.00% 10-Q · filed 2020-08-05 | |||||
| 2019-12-31 | 0.00% 10-K · filed 2021-03-30 | |||||
| 2019-09-30 | 0.00% 10-Q · filed 2020-11-16 | |||||
| 2019-06-30 | 0.00% 10-Q · filed 2020-08-05 | |||||
| 2019-02-01 | 0.00% 10-Q · filed 2019-11-12 | 0.00% 10-Q · filed 2020-11-16 | ||||
| 2018-12-31 | 0.00% 10-K · filed 2020-02-14 | |||||
| 2018-09-30 | 0.00% 10-Q · filed 2018-11-13 | |||||
| 2018-06-30 | 0.00% 10-Q · filed 2019-08-09 | |||||
| 2018-03-31 | 0.00% 10-Q · filed 2019-05-10 | |||||
| 2017-12-31 | 0.00% 10-K · filed 2019-03-15 | |||||
| 2017-09-30 | 0.00% 10-Q · filed 2018-11-13 | |||||
| 2017-06-30 | 0.00% 10-Q · filed 2018-08-13 | |||||
| 2016-12-31 | 0.00% 10-K · filed 2018-03-28 | |||||
| 2016-09-30 | 0.00% 10-Q · filed 2017-11-13 | |||||
| 2016-06-30 | 0.00% 10-Q · filed 2017-08-14 | |||||
| 2015-12-31 | 0.00% 10-K · filed 2017-03-29 | |||||
| 2015-09-30 | 0.00% 10-Q · filed 2016-11-14 | |||||
| 2015-06-30 | 0.00% 10-Q · filed 2016-08-12 | 0.00% 10-Q · filed 2015-08-11 | ||||
| 2015-03-31 | 0.00% 10-Q · filed 2016-05-12 | |||||
| 2014-12-31 | 0.00% 10-Q · filed 2016-05-12 | |||||
| 2014-09-30 | 0.00% 10-Q · filed 2014-11-13 | |||||
| 2014-06-30 | 0.00% 10-Q · filed 2014-08-11 | |||||
| 2014-03-31 | 0.00% 10-Q · filed 2014-05-15 | |||||
| 2013-12-31 | 0.00% 10-K · filed 2015-03-31 | |||||
| 2013-09-30 | 0.00% 10-Q · filed 2014-11-13 | 0.00% 10-Q · filed 2013-11-18 | ||||
| 2013-06-30 | 0.00% 10-Q · filed 2014-08-11 | |||||
| 2012-12-31 | 0.00% 10-K · filed 2014-03-31 | |||||
| 2012-09-30 | 0.00% 10-Q · filed 2013-11-18 | 0.00% 10-Q · filed 2013-11-18 | ||||
| 2012-06-30 | 0.00% 10-Q · filed 2013-08-09 | |||||
| 2011-12-31 | 0.00% 10-K · filed 2013-04-01 | |||||
| 2011-09-30 | 0.00% 10-Q · filed 2012-11-14 | 0.00% 10-Q · filed 2012-11-14 | ||||
| 2011-06-30 | 0.00% 10-Q · filed 2012-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |